Request COAs & Samples

    Varin Cannabinoids (THCV, CBDV and others)
    • THCV and CBDV Isolates (>98% Purity)
    • 100% THC-Free
    • Naturally-occurring Varin Molecules for More Effective Plant Medicine and Remedies

    Varin Cannabinoids (THCV, CBDV and others)

    The varinolic cannabinoids are considered rare but are now emerging as new targets of selective breeding. None of the varins are scheduled as a controlled substance.  Nor are they analogues of any such substances.

    CBVD isolate is a crystallized powder. THCV isolate is a solid at room temperature and highly subject to oxidative discoloration. The purity of these varins (>98% pure) have been tested by HPLC, GCMS, LC-MS, NMR, IR, melting point, and elemental analysis. All analytical test results demonstrated the high quality and purity of PPM’s varin isolates.

    Two of the varins – CBDV and THCV – have shown to have medicinal and wellness properties. Varins contain two fewer carbon atoms than their non-varin counterparts (CBD and THC) making these cannabinoids fundamentally different on a molecular level and therefore have different physiological effects due to different binding in the endocannabinoid system.

    Varin Cannabinoids (THCV, CBDV and others)

    Tetrahydrocannabivarin (THCV)— THCV can decrease signs of inflammation and inflammatory pain, a combination that could be useful in topical analgesics. (Hyperlink 6) THCV also has been found to suppress basal sebaceous lipid synthesis, which could help acne sufferers whose condition is triggered by excessive oil production. Experimental Dermatology noted that of all of the phytocannabinoids examined, THCV showed the most promise of becoming a “highly efficient, novel anti-acne agent.” (Hyperlink 1) THCV is also a new potential cannabinoid to treat obesity, diabetes, and promote weight loss by indirect binding to the CB1 receptor of the endocannabinoid system. (Hyperlink 7)

    Continuous research and reliable data will demonstrate the need for these rare cannabinoids providing opportunities for brands in the plant-based health and wellness sector.

    Cannabidivarin (CBDV)—Recent studies indicate CBDV may help dry skin syndrome as well as acne. (Hyperlink 1) Researchers also found that CBDV may reduce allergic inflammation, atopic dermatitis, acne and seborrhea (a.k.a. dandruff). (Hyperlink 2) These properties could make CBDV ideal for incorporating into hypoallergenic products, or topicals designed for sensitive, itch-prone skin. Anticonvulsant properties of CBDV/ CBD were reported by suppressing an epilepsy gene providing evidence of the entourage effect as well as the importance of unique ratios and formulations. (Hyperlink 3 and 4) This research strongly supports the potential of CBDV as a potential treatment of epilepsy. In fact, GW Pharmaceuticals is conducting a human trial to treat epilepsy with CBDV. (Hyperlink 5)

    1. Hyperlink 1: https://pubmed.ncbi.nlm.nih.gov/27094344
    2. Hyperlink 2: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429381/
    3. Hyperlink 3: https://pubmed.ncbi.nlm.nih.gov/23902406
    4. Hyperlink 4: https://pubmed.ncbi.nlm.nih.gov/24282673
    5. Hyperlink 5: http://www.globenewswire.com/news-release/2014/03/17/618576/10072767/en/GW-Pharmaceuticals-Provides-Update-on-Cannabinoid-Pipeline.html
    6. Hyperlink 6: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2931567/
    7. Hyperlink 7: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3671751/
    All studies reported here have been published in the scientific peer-reviewed literature. From our survey and in our judgement, the articles cited are recent and relevant to the potential health and wellness benefits of rare cannabinoids but does not include all literature that exists. It must be noted that most clinical trials have been performed on the animal model or in vitro on cells. More research is required including human trials to demonstrate and understand efficacy, serving and dosing sizes, potential side effects, effects on at-risk populations, and drug interactions related to the use of minor cannabinoids. 

    Technical Data Sheet

    THCV Technical Data Sheet

    CBDV Technical Data Sheet

    Frequently Asked Questions:

    PPM rigorously tests all products prior to shipment to customers for purity, contaminants, and character to ensure product integrity and all specifications are met or exceeded.
    A credentialed, experienced full-time Analytics Lab Manager at PPM supervises all in-house testing using advanced analytical instruments, methods, software and techniques.  Instruments like gas chromatograph – mass spectrometers (GCMS) with headspace and FID detectors, high performance liquid chromatography (HPLC), nuclear magnetic resonance (NMR) and other testing is conducted during processing, development and continuous improvement activities, and of course, extensively by PPM PhD scientists conducting R&D initiatives.
    PPM’s intellectual property encompasses many advances in testing for the complex and hard to distinguish cannabinoid isomers that can be a byproduct of processing to achieve >99% purity of a single isolated naturally occurring cannabinoid.  Similarly, PPM has pioneered quantification and qualification techniques to ensure contaminants are fully removed prior the final QA/QC for its  bulk cannabinoids that are to be used as essential ingredients in products.
    PPM’s primary business value is safety of products and people.  PPM’s analytical testing team ensures at multiple processing steps, the final wholesale cannabinoid ingredients are standardized and consistent made to pharma-grade levels.
    Basically, PPM defines minor and rare cannabinoids as those other than CBD and CBG.  Specifically, cannabinoids that have bioactivity in mammals (humans and pets!) that are used as cannabinoid ingredients for their health and wellness and medicinal properties.
    Cannabinoids like Cannabinol (CBN), Cannabichromene (CBC), Cannabidiolic Acid (CBDA), Cannabigerolic Acid (CBGA), Tetrahydrocannabivarin (THCV), Cannabidivarin (CBDV), Cannabicitran (CBT) and others that are isolated and purified by proprietary processing to yield pure, clean and compliant ingredients.
    For each minor and rare cannabinoid that PPM produces and sells, PPM includes technical data sheet describing all product specifications for purity and characteristics, a Safety Data Sheet (SDS) conforming to the US standard for such documentation, and a Certificate of Analysis (COA).
    Bulk or wholesale cannabinoids are sold to product formulated and manufacturers, not directly to end-use personal consumers.
    Why? Ease and convenience of formulating CPG products. The ability to enrich or fortify plant extracts that vary harvest to harvest with standardized and known cannabinoid profiles.  Manufacturers can label their products for consumers with specific dosing amounts in milligrams in a suggested serving size.
    Bulk cannabinoids are typically the most cost-effective pathway to making distinctive, efficacious and innovative cannabinoid-based products.
    Getting started is as simple as communicating, ideally in a phone call, with PPM’s sales director.
    PPM is focused on serving global leaders in the CPG, hemp/CBD, licensed THC, and other markets.  PPM’s business is tailored to bulk, kilogram quantity and above, sales of minor and rare cannabinoids to consumer product formulators and manufacturers.
    Yes.
    In order to serve customers as a one-stop supplier, to minimize supply chain complexity and assure all bulk ingredients for a production run arrive at the same time, and other factors, PPM customers find buying CBD isolate and CBG isolate from PPM to be advantageous. Depending on the order size, PPM will provide custom formulations as specified by its wholesale customers.
    The purpose of a COA is to know the character of the sample tested – how pure? how clean of contaminants?
    The definition of a COA is a formal, written report clearly showing the testing results as defined in the report itself including what specific testing was conducted, the analytical instrumentation employed, and the testing methodology’s Limit of Detection (LOD) and Limit of Quantification (LOQ).
    Much confusion exists about COAs in the cannabinoid industry ranging from their accuracy to their consistency when different analytical labs test split samples to their purpose and for that matter, their limitations. Let’s tackle the issues one at a time.
    The most common COA is a potency report that presents the panel of cannabinoids to be identified and their percentage.  For example, the COA may show that 15 individual cannabinoids were part of the testing panel, and the sample tested was comprised of 99% CBN and 1% unknown material.  Based on the LOD and LOQ as described in the COA, a reporting of 1% unknown material would solely mean that the other 14 cannabinoids in the test panel other than CBN were not found in the sample.  The concentration levels chosen for a particular sample to be tested is also important and most often when testing minor and rare cannabinoids the analytic testing needs to be done twice at two different concentration levels to present an accurate picture of the % constituents are, particularly the other cannabinoids beside the isolated cannabinoid, in a sample.  When testing high purity cannabinoid isolateds, many third-party testing labs do not test at two concentrations unless they are specifically asked to do so and paid accordingly.
    Other common COA reports are tests for residual solvents and other contaminants like heavy metals, microbials and mycotoxins.
    Accuracy and consistency when comparing reported test results from two different analytical laboratories, or even when comparing trusted in-house analytical lab vs an independent third-party analytical lab is a common complaint in the cannabinoid industry.  Although accuracy and consistency is rapidly improving industry-wide, several factors account for frustration by product manufacturers who require confirmation of the integrity of the bulk cannabinoid ingredients they source from suppliers and use in their products.  Factors like the relatively immaturity of the cannabinoid testing industry, the fact that standardized methodologies are still being established, inexperience in testing minor and rare cannabinoids by analytical labs most familiar with commodity hemp/CBD ingredients like CBD and CBG and CBD distillate, and even sampling techniques that are not uniform even within a testing lab.
    The limitations that is experienced in the analytical testing field can best be addressed with split samples, an understanding that fairly large margins of error still exist industry-wide, COAs can be falsified easily by unscrupulous market participants,
    What does a Third-Party Accredited Lab COA mean and does PPM have them for its cannabinoid isolates?
    A third-party lab is an independent lab paid to test a sample of material, in this case, a minor or rare cannabinoid isolate, concentrate, extract, oil or distillate.  An accredited lab is defined as one that is ISO 17025 certified by an auditing firm and issued a certificate of compliance with the ISO specifications related to analytical lab testing.  Most independent labs need to obtain such certification.  In-house labs sometimes obtain accreditation but are not required to do so.
    PPM obtains COAs from accredited independent (third-party) labs for its isolate products.  PPM also have invested heavily in internal analytical testing that often is superior in accuracy, consistency, precision and scope as compared to external labs.  PPM tests extensively during processing as part of its quality management system (QMS) to ensure each step of processing remains “in-spec” as well as part of PPM’s final QA/QC process.
    Yes. Simply give our Sales Director a call or ask to be contacted by PPM and we will talk through your testing and assessment needs and get you started.
    Simply give our Sales Director a call or ask to be contacted by PPM.  Order quantity, future frequency and order amounts, special requirements and any other topics can be discussed so we can serve as your trusted supply chain partner for cannabinoid isolates and concentrates.
    Technically, PPM does not have a MOQ.  PPM’s goal is to help as many consumers as possible with the benefits of minor cannabinoids for health and wellness and lifestyle choices.  We want our wholesale product formulation and manufacturing customers to be successful.
    PPM has found that many companies are just getting started with formulating with minor and rare cannabinoids and don’t have a forecast for their future requirements.
    PPM will often provide bulk pricing for small “starter” purchase orders to allow new and smaller manufacturers to be successful with their new product launches.  Our goal is to be your partner as you grow.
    PPM tailors the most cost-effective pricing matrix to your actual requirements taking into account many factors.  Since PPM only sells bulk and wholesale, pure, clean cannabinoid isolates to commercial customers in commercial quantities, pricing is tailored and often justifies changes with volume growth, market pricing trends, and other factors.
    PPM is led by a team of advanced-degreed scientists with pharmaceutical industry and university research backgrounds representing over 100 years of chemistry and plant medicine experience. 
     
    PPM is committed to advancing the science and providing minor and rare cannabinoid bulk ingredients, both 100% hemp-derived and biosynthesized from precursors versions (CBN, CBC, CBT, CBDA, CBGA, THCV, CBDV, etc.), to leading consumer product supply chains worldwide. Our goal is to be a trusted supply chain partner to industry leaders. 

    PPM is the actual producer.  PPM is the largest scale producer and can pass along economies of processing scale to its customers.  PPM’s supply chain can be vetted and audited by demanding customers.

    Personalized cannabinoid medicine is the goal.  Clean.  Consistent.  Compliant.  
    Every day, every team member at PPM is inspired by the possibilities of plant-based medicine and remedies, and Mother Nature’s genius.

    PPM wholesales bulk ingredients intended for dilution and formulation prior to sale to end-use customers.

    These statements have not been evaluated by the Food and Drug Administration.  Any product mentioned is not intended to diagnose, treat, cure, or prevent any disease. 

    Sign Up For PPM’s Newsletter

    Enter Email Address